Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — AmpliPhi Biosciences — Investor Presentation (January 2016)
19 slides from Armata Pharmaceuticals's investor presentation, Jan 11, 2016
Slide 1: A Global Leader in Bacteriophage Development to Combat Infectious Diseases
A Global Leader in Bacteriophage Development to Combat Infectious Diseases January 2016
Slide 2: Forward-looking statements
Statements in this presentation that are not statements of historical fact are forward - looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward - looking statements include, without limitation, statements regarding the expected timing of firs
Slide 3: Key Messages
Key Messages Urgent M arket N eed • Addressing an acknowledged world - wide health crisis in antimicrobial resistance (AMR ) Unique Bacteriophage P latform T echnology • Novel mechanism of action compared to current antibacterial treatment paradigm • Deploying synthetic biology techniques to improve
Slide 4: AMR: A Major Global Health Threat
AMR: A Major Global Health Threat We are approaching a post - antibiotic e ra* • S. aureus: >850,000 ** patients in US were treated for skin or soft tissue infection • Due to therapeutic failure, over 50% treated with a second - line agent, 35% with a third - line agent • Pseudomonas: Primary lung i
Slide 5: Bacteriophage Therapy: Harnessing Eons of Evolution to Defeat Drug Resistance Infections
Bacteriophage Therapy: Harnessing Eons of Evolution to Defeat Drug Resistance Infections What are bacteriophage? • Natural predator of bacteria • Most abundant life - form on Earth • Evolved to be strain - specific Why now? • Humans co - evolved with phage, a key component of our microbiota • NexGen
Slide 6: Bacteriophage Kill only Targeted Bacteria
Bacteriophage Kill only Targeted Bacteria Bacteriophage encounters target bacterial cell Bacteriophage binds to target cell and injects DNA Bacteriophage converts cell into bacteriophage “factory” Cell bursts, releasing new generation bacteriophages Process repeats as new bacteriophages encounter ta
Slide 7: Phage Therapies Today and into the Future
Phage Therapies Today and into the Future Phage v 1.0 Wild type phage and host Cocktails • Expand host range • Reduce resistance • Target “Keystone” pathogens Phage v 2.0 Polyvalent, strain - specific phage • Further expand host range • Limit overall phage number in cocktail Host engineering v 3.0 a
Slide 8: Corporate Leadership
Corporate Leadership Prior Management Experience M. Scott Salka Chief Executive Officer David Bosher iChief Financial Officer Wendy S. Johnson iChief Operating Officer Alexander Gaidamaka D.V.M., Ph.D. VP CMC 8
Slide 9: World Leading Programs And Collaborations
World Leading Programs And Collaborations 9 Product Disease Collaborator R&D Timeline AB - SA01 S. a ureus Chronic Rhinosinusitis Phase I H2 2015 Phase II H1 2017 AB - SA01 S. aureus Wounds Phase I H 1 2016 AB - PA01 P. aeruginosa Cystic Fibrosis Phase I H 1 2017 AB - PA01 P. aeruginosa Chronic Rhin
Slide 10: Bacteriophage Pipeline
Bacteriophage Pipeline
Slide 11: Dedicated cGMP-Certified Bacteriophage Manufacturing Facility in Ljubljana, Slovenia
Dedicated cGMP - Certified Bacteriophage Manufacturing Facility in Ljubljana, Slovenia Proprietary host and phage banks Passed numerous GMP audits with no major findings • Now capable of supporting clinical trials Current serial manufacturing capability with the ability evolve into a geographically
Slide 12: AB-SA01 for the Treatment of S. aureus (MRSA) Infections
AB - SA01 for the Treatment of S. aureus (MRSA) Infections Two Projects Underway • Chronic Rhinosinusitis: Clinical trial with University of Adelaide’s Queen Elizabeth Hospital • Phase I safety clinical trial exploring two doses and two schedules • Currently screening patients • Expected data H2 201
Slide 13: AB-PA01 for the Treatment of P. aeruginosa Infections
AB - PA01 for the Treatment of P. aeruginosa Infections Two Projects Underway: • Cystic Fibrosis : Royal Brompton Hospital (major UK CF treatment center) focused on chronic infections in CF patients • cGMP manufacturing 2016 • GLP inhalation tox to support clinical program targeted H2 2016 • MHRA su
Slide 14: AB-PA01 Studies Demonstrate Efficacy in Lung Infection Model Comparable to High-Dose Cipro
AB - PA01 Studies Demonstrate Efficacy in Lung Infection Model Comparable to High - Dose Cipro Luminescent Pseudomonas Response to Treatment of Established Infection in Murine Lung Efficacy summary • Phage therapy rapidly controls infection • P hages infect and kill antibiotic resistant and sensitiv
Slide 15: AB-CD01 for the Treatment of Chronic C. difficile Infections
AB - CD01 for the Treatment of Chronic C. difficile Infections Two Projects Underway • CDI/CDAD: License with University of Leicester and leading expert Professor Martha Clokie • Identify lytic C. difficile phage candidates • Efficacy demonstrated in animal model (manuscript accepted) • Expected dru
Slide 16: Highlights
Highlights
Slide 17: Near-Term Goals
Near - Term Goals Clinical Trials • Begin dosing chronic sinusitis patients with S. aureus infections expected during Q1 2016. Data expected H2 2016 • File US IND for topical application of S. aureus phage mix in January 2016. Data expected H2 2016 Expanding Pipeline • Expect to complete manufacture
Slide 18: Key Messages
Key Messages Urgent M arket N eed • Addressing an acknowledged world - wide health crisis in antimicrobial resistance (AMR ) Unique Bacteriophage P latform T echnology • Novel mechanism of action compared to current antibacterial treatment paradigm • Deploying synthetic biology techniques to improve
Slide 19: For additional information
For additional information Investor Relations AmpliPhi Biosciences ir@ampliphibio.com
AmpliPhi Biosciences — Investor Presentation (January 2016) on 6ix